Lung Cancer Surgery after Neoadjuvant Immunotherapy

In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies.

Preview

Category

Date Issued:
10.08.2021
URN:
urn:nbn:de:hbz:465-20220520-135733-1
DOI:
10.3390/cancers13164033
Language:
English
Type of Resource:
Text
Publisher:
MDPI AG
Keywords:
lung cancer surgery; neoadjuvant immunotherapy
Collection:
E-Publications
Subject categories of the Deutsche Nationalbibliografie:
610 Medical sciences Medicine
Hosting institution:
Faculty of Medicine, Essen University Hospital, Ruhrlandklinik Essen – Universitätsklinik
Hosting institution:
Faculty of Medicine, Essen University Hospital, Radiation and Tumor Clinic
Hosting institution:
Faculty of Medicine, Essen University Hospital, Clinic for Internal Medicine (Tumor Research)
Info on primary publication:

Stefani D, Plönes T, Viehof J, Darwiche K, Stuschke M, Schuler M, Aigner C. (2021). Lung Cancer Surgery after Neoadjuvant Immunotherapy. Cancers. 13(16):4033. https://doi.org/10.3390/cancers13164033

Published: 10 August 2021

version identification:
Version of Record / Verlagsversion
funding:

The publication of this article was supported by the Publication Fund of the University of Duisburg-Essen.

Cite

Citation style:
Could not load citation form.

Rights

License Holder:

© 2021 by the authors

Use and reproduction:
This work may be used under a
CC BY 4.0 LogoCreative Commons Attribution 4.0 License (CC BY 4.0)
.